Cyclic peptides and cyclic peptide conjugates for treating neurological disorders
Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and/or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.
1. A method of treating morphine addiction in an individual in need thereof, the method comprising administering to the individual via intranasal delivery to the individual's brain a composition comprising: i) a cyclic peptide conjugate comprising the amino acid sequence naloxone-C 1 A 2 S 3 P 4 K 3 -cyclo[C 6 F 7 R 8 Y 9 P 10 N 11 G 12 V 13 L 14 A 15 C 16 ]T 17 (SEQ ID NO: 17), and ii) a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the individual is a mammal.
3. The method of claim 1 , wherein the naloxone is a therapeutic agent and the composition further includes a second therapeutic agent that is a drug that targets opioid receptors, dopamine receptors, serotonin receptors, or cannabinoid receptors.
4. A method of treating cocaine addiction in an individual in need thereof, the method comprising administering to the individual via intranasal delivery to the individual's brain a composition comprising: i) a cyclic peptide conjugate comprising the amino acid sequence 5-HTrp 1 -A 2 S 3 P 4 K 5 -cyclo[C 6 F 7 R 8 G 9 F 10 W 11 P 12 K 13 L 14 A 15 C 16 ]T 17 (SEQ ID NO: 13) and ii) a pharmaceutically acceptable carrier, wherein 5-HTrp 1 -A 2 S 3 P 4 K 5 -cyclo[C 6 F 7 R 8 G 9 F 10 W 11 P 12 K 13 L 14 A 15 C 16 ]T 17 SEQ ID NO: 13 accumulates in the individual's brain and has k opioid receptor (KOR) agonist activity in the brain.
5. The method of claim 4 , wherein the individual is a mammal.
6. The method of claim 4 , wherein the 5HTrp is a therapeutic agent and the composition further includes a second therapeutic agent that is a drug that targets opioid receptors, dopamine receptors, serotonin receptors, or cannabinoid receptors.